Tiotropium: An inhaled anticholinergic for chronic obstructive pulmonary disease

American Journal of Health-System Pharmacy

Volumn 62, Issue 12, 2005, Pages 1263-1269

  Olin, Jacqueline L ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b Hunterdon Medical Center   (United States)

Author keywords

Blood levels; Compliance; Dosage; Dosage schedules; Drug administration; Drug comparisons; Drug interactions; Formularies; Inhalers; Ipratropium; Lung diseases; Mechanism of action; Parasympatholytic agents; Patients; Pharmacokinetics; Quality of life; Salmeterol

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CORTICOSTEROID; FORMOTEROL; IPRATROPIUM BROMIDE; PLACEBO; PREDNISONE; RANITIDINE; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ANTICHOLINERGIC EFFECT; BRONCHODILATATION; BRONCHOSPASM; CHOLINERGIC ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONSTIPATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PACKAGING; FOOD AND DRUG ADMINISTRATION; FORCED EXPIRATORY VOLUME; HUMAN; INHALER; METERED DOSE INHALER; MUCUS SECRETION; PATIENT COMPLIANCE; PRIORITY JOURNAL; QT INTERVAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TACHYCARDIA; VISUAL IMPAIRMENT; VITAL CAPACITY; XEROSTOMIA;

EID: 20544459091     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.12.1263     Document Type: Review

References (27)

1. National Heart, Lung, and Blood Institute. Chronic obstructive pulmonary disease data fact sheet, www.nhlbi.nih.gov/ health/public/lung/other/copd_fact. pdf (accessed 2005 Mar 15).
2. European Respiratory Society and the American Thoracic Society. Standards for the diagnosis and management of patients with COPD, June 2004. www. ersnet.org/ers/viewer_COPD/mainFrame/ default.aspx (accessed 2004 Jul 21).
3. Sutherland ER, Cherniak RM. Management of chronic obstructive pulmonary disease. N Engl J Med. 2004; 350:2689-97.
4. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Workshop report, www.goldcopd.com (accessed 2004 Jul 21).
5. Spiriva HandiHaler (tiotropium bromide inhalation powder) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc.; 2004 Jan.
6. Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther. 2003; 98:59-69.
7. On LS, Boonyongsunchai P, Webb S et al. Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001; 163:1320-5.
8. Disse B, Speck GA, Rominger KL et al. Tiotropium: mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999; 64:457-64.
9. Turck D, Weber W, Sigmund R et al. Pharmacokinetics of intravenous single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol. 2004; 44:163-72.
10. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001; 56:880-7.
11. Crapo RO. Pulmonary function testing. In: Baum GL, Crapo JD, Bartolome RC et al., eds. Textbook of pulmonary diseases. 6th ed. Philadelphia: Lippincott-Raven; 1998:204-7.
12. Sato S, Nishimura K, Tsukino M et al. Possible maximal change in the SF-36 of outpatients with chronic obstructive pulmonary disease and asthma. J Asthma. 2004; 41:355-65.
13. Mahler DA, Weinberg DH, Wells CK et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984; 85:751-8.
14. Witek TJ Jr, Mahler DA. Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003; 56:248-55.
15. Wilson CB, Jones PW, O'Leary CJ et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med. 1997; 156: 536-41.
16. Curtis JR, Patrick DL. The assessment of health status among patients with COPD. Eur Resp J Suppl. 2003; 41:36S-45S.
17. Wyrwich KW, Fihn SD, Tierney WM et al. Clinically important changes in health-related quality of life for patients with chronic obstructive pulmonary disease: an expert consensus panel report. J Gen Intern Med. 2003; 18:196-202.
18. Casaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002; 19:217-24.
19. Vincken W, van Noord JA, Greefhorst AP et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002; 19:209-16.
20. Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002; 122:47-55.
21. Brusasco V, Hodder R, Miravitlles M et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003; 58:399-404.
22. Barr RG. Management of chronic obstructive pulmonary disease. JAMA. 2004; 291:1066-7. Letter.
23. Cazzola M, Di Marco F, Santus P et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther. 2004; 17:35-9.
24. Dahl R, Backer V, Ollgaard B et al. Assessment of patient performance of the HandiHaler compared with the metered dose inhaler four weeks after instruction. Respir Med. 2003; 97:1126-33.
25. Food and Drug Administration. Tiotropium application response letter. www.fda.gov/cder/foi/appletter/2004/ 21395ltr.pdf (accessed 2004 Jul 21).
26. Fleming T, ed. Drug topics red book. Montvale, NJ: Thompson PDR; 2004.
27. Boehringer-Ingelheim. Chronic obstructive pulmonary disease, www. boehringer-ingelheim.com/corporate/ products/prod_prescr_copd.htm (accessed 2004 Nov 1).